Overview

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Status:
Completed
Trial end date:
2019-02-14
Target enrollment:
0
Participant gender:
All
Summary
The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
Pfizer
Treatments:
Anti-Retroviral Agents
Maraviroc
Criteria
Inclusion Criteria:

- Treatment experienced, HIV-1 infected patients

- 18 years or older

- Receive an approved assay for determination of HIV-1 tropism

Exclusion Criteria:

- Pregnant or lactating

- Using CCR5 inhibitor other than maraviroc